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Abstract
The prevalence of the metabolic syndrome components including abdominal obesity, dyslipidaemia and insulin resistance is increasing in both
developed and developing countries. It is generally accepted that the development of these features is preceded by, or accompanied with,
impaired mitochondrial function. The present study was designed to analyse the effects of a mitochondrial-targeted lipophilic ubiquinone (MitoQ)
on muscle lipid proﬁle modulation and mitochondrial function in obesogenic diet-fed rats. For this purpose, twenty-four young male Sprague–
Dawley rats were divided into three groups and fed one of the following diets: (1) control, (2) high fat (HF) and (3) HF+MitoQ. After 8 weeks,
mitochondrial function markers and lipid metabolism/proﬁle modiﬁcations in skeletal muscle were measured. The HF diet was effective at
inducing the major features of the metabolic syndrome – namely, obesity, hepatic enlargement and glucose intolerance. MitoQ intake prevented
the increase in rat body weight, attenuated the increase in adipose tissue and liver weights and partially reversed glucose intolerance. At the muscle
level, the HF diet induced moderate TAG accumulation associated with important modiﬁcations in the muscle phospholipid classes and in the fatty
acid composition of total muscle lipid. These lipid modiﬁcations were accompanied with decrease in mitochondrial respiration. MitoQ intake
corrected the lipid alterations and restored mitochondrial respiration. These results indicate that MitoQ protected obesogenic diet-fed rats from
some features of the metabolic syndrome through its effects on muscle lipid metabolism and mitochondrial activity. These ﬁndings suggest that
MitoQ is a promising candidate for future human trials in the metabolic syndrome prevention.
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The metabolic syndrome is a clustering of cardiovascular risk
factors, including abdominal obesity, dyslipidaemia, mitochondrial
dysfunction and insulin resistance (IR)(1). Its prevalence is high in
both developed and developing countries, where obesity and its
related problems are increasing rapidly. Increased consumption of
energy-dense foods containing high amounts of animal fats, SFA
and fructose is thought to be the major contributor to the current
epidemic of metabolic disorders(2). In addition to the chronic
imbalances between energy supply and energy demands, there
are many studies conﬁrming that increased availability of SFA
in muscle and liver is associated with IR(3,4). Muscle TAG
accumulation could occur because of increased availability and
uptake of systemic free fatty acids (FFA)(5). Another possibility is
that impaired muscle fatty acid oxidation (even in the presence of
unaltered uptake) leads to excess cytosolic lipid accumulation(6,7).
The relative contribution of the different sources of excess lipid to
muscle is not currently known in quantitative terms, and a com-
bination of both factors (oversupply and impaired oxidation) may
be a possibility. Although TAG accumulation is not a problem
per se and can even be protective, the intracellular accumulation
of long-chain CoA or various lipid derivatives is known to be
disruptive. Mitochondrial FFA oxidation may inﬂuence glucose
oxidation via the classic glucose–fatty acid (Randle) cycle(8).
Changes in the level of speciﬁc fatty acids could result in
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production of other lipid species (e.g. speciﬁc diacylglycerols
(DAG)) that may alter insulin signalling pathways via protein
kinase C activation(9,10). Ceramides can also be generated from
increased lipid availability and are known to be among the most
active lipid second messengers to inhibit the insulin signalling
pathway(11).
Mitochondria are central to energy metabolism, as they are
involved in the process of oxidative phosphorylation (OXPHOS),
converting the energy stored in nutrients into ATP through the
action of the mitochondrial respiratory chain complexes reducing
O2 to water. There is a relationship between IR and diminished
mitochondrial function(12). Therefore, given the central position of
mitochondria and their key roles in energy metabolism and in the
development of the metabolic syndrome, many therapies
designed to prevent mitochondrial dysfunction have been
developed(13–15). Among these mitochondrial-targeted therapies,
the antioxidant mitochondrial-targeted lipophilic ubiquinone
(MitoQ) is widely used and has shown protection against oxidative
damage in a wide range of pathologies(16,17), but little is known
about its role in high-fat diet (HFD)-induced obesity models(18–20).
This study was designed to determine the impact of MitoQ on
obesity, glucose intolerance and IR development in obesogenic
diet-fed rats, independent of its antioxidant action. Indeed, it is
likely that MitoQ can impact on other important physiological
mechanisms, particularly through direct effects on both lipid
metabolism and mitochondrial activity. In line with this, it was
reported that co-enzyme Q analogues may be considered as
anti-adipogenic/anti-obesity factors(21).
This report focused on the skeletal muscle because it is the
principal tissue for postprandial insulin-stimulated glucose disposal,
and thus the key regulator of glucose homoeostasis. The results
suggest that MitoQ protected rats exposed to a HFD from some
features of the metabolic syndrome through positive muscle lipid
metabolism modulation and improved mitochondrial respiration.
Methods
Chemicals and apparatus
MitoQ was provided by R. A. J. Smith from the University
of Otago in New Zealand. Peroxidase from horseradish,
2',7'-dichloroﬂuorescein, ADP, succinate, malate, glutamate,
and oligomycin were purchased from Sigma. Rhodamine 123
was purchased from ICN Biomedical. NADPH was purchased
from Calbiochem Merck. All other chemicals used were of the
highest grade and obtained from Sigma Aldrich or Prolabo. LS
45 Fluorescence spectrometer (PerkinElmer) was used for
ﬂuorescence measurements. The Nicolet Evolution 100
spectrophotometer (Thermo Electron Corporation) was used
for absorbance measurements.
Animals and diets
In all, twenty-four 6-week-old male Sprague–Dawley rats,
weighing 175–200 g (Charles River) were housed two per cage
under conditions of constant temperature (20–22°C), humidity
(45–50%) and a standard dark cycle (20.00–08.00 hours). The
rats were randomised into three groups of eight animals each
and were fed for 8 weeks one of the following semi-puriﬁed
diets: (1) control diet with 4% lipid as soyabean oil, (2) HFD
and (3) HFD with MitoQ (HF-MitoQ). The control diet
contained 20% protein, 66% carbohydrate, 4% fat (soyabean
oil) w/w plus cellulose and vitamin and mineral mix. The
HFD contained 20% protein, 35% carbohydrate, 35% fat
(4% soyabean oil + 31% lard) w/w plus cellulose and vitamin
and mineral mix. MitoQ was used at a dose of 860mg/kg diet in
the form of methanesulfonate β-cyclodextrin complex, which
corresponded to 375 µmol of MitoQ/kg diet. Rats were given
free access to tap water and food. Body weight and food
consumption were determined weekly. Our institution
guidelines for the care and use of laboratory animals were
observed, and all the experimental procedures were approved
by the local ethics committee (reference CEEA-LR-12002). This
report is part of a larger study where the effects of other
antioxidants (apocynin, allopurinol and N-acetyl-cysteine) have
been investigated and published elsewhere(22).
Oral glucose tolerance test
The oral glucose tolerance test (OGTT) was performed as
previously described(23). In brief, on week 7 of diet intake, after 16h
of fasting, rats received by gavage 2g glucose/kg body weight.
Blood was sampled through the tail vein of conscious rats
immediately before the gavage and 20, 40, 60, 90, 120 and 180min
afterward, and the blood glucose level was measured using glucose
strips and a commercial glucometer (Accu-Chek Active; Roche
Diagnostics). The AUC values were calculated by the trapezium
method. The AUC values are expressed as mmol glucose/l per s.
Killing of rats and metabolic biochemical analyses
After 4–5d of the OGTT, after 16h of fasting, rats were
anaesthetised with pentobarbital (40mg/kg body weight) (Ceva
Santé Animale), and blood samples were collected from the
abdominal artery with a heparinised syringe and distributed into
heparinised and dry tubes. Blood tubes were centrifuged at 1000 g
for 10min at 4°C, and plasma or serum samples were collected and
stored at −80°C until analysis. Both gastrocnemius were removed
and one of them was used for the extemporaneously isolation of
fresh muscle mitochondria. The other gastrocnemius as well as the
soleus muscles and the liver and the visceral fat were collected,
rinsed and weighed.
Plasma glucose, serum total cholesterol, TAG and NEFA
levels were measured by enzymatic techniques (Thermo
Electron Corp.). Plasma insulin, leptin, TNF-α and IL-6 levels
were quantiﬁed using ELISA kits (St Charles). IR was evaluated
by the homoeostasis model assessment of IR (HOMA-IR)
formula: (fasting plasma glucose level (mmol/l)× fasting plasma
insulin level (mIU/l))/22·5(24).
Muscle expression of TNF-α and IL-6 cytokines
The muscle mRNA expressions of TNF-α and IL-6 genes were
determined by RT-quantitative PCR as previously reported(22).
Normalisations were made to RPS9. The following primer
sequences were used: forward TNF-α – GGC ATG GAT CTC
1156 C. Coudray et al.
http://dx.doi.org/10.1017/S0007114515005528
Downloaded from http:/www.cambridge.org/core. Open University Libraryy, on 22 Dec 2016 at 22:09:25, subject to the Cambridge Core terms of use, available at http:/www.cambridge.org/core/terms.
AAA GAC AAC C; reverse TNF-α – CAA ATC GGC TGA CGG
TGT G (accession no. NM_012675.3); forward IL-6 – CTC CGG
ACT TGT GAA GTA GGG; reverse IL-6 – ATG AAG TTT CTC
TCC GCA AGA (accession no. NM_012589.1); forward RPS9 –
GAA GCT GGG TTT GTC GCA AA; and reverse RPS9 – CGG
AGC CCA TAC TCT CCA AT (accession no. NM_031108.4).
Western blotting analyses for determining muscle TNF-α and
IL-6 protein expressions were carried out as previously
reported(22). β-Actin was used as reference, and blot intensities
were measured using ImageJ software (NIH). Antibodies of
TNF-α (ab66579) and IL-6 (ab6672) were from Abcam and
β-actin antibody (s-c81178) was from Santa Cruz Biotechnology.
Mitochondrial membrane potential, respiration and
reactive oxygen species production
Muscle mitochondria were isolated by the differential centrifugation
technique(25). The protein content of muscle supernatants and
mitochondrial suspensions was determined according to Bradford
using bovine serum albumin as the standard(26).
Mitochondrial membrane potential was monitored according
to the method described by Baracca et al.(27) using rhodamine
as a probe. Mitochondrial potential (Δψ) change has been
evaluated by measuring rhodamine ﬂuorescence at the following
steps: with rhodamine label alone (2 µM) in MIRO5 buffer plus
muscle fresh mitochondria (0·25mg proteins), plus glutamate–
malate–succinate (2·5:5:5M), plus ADP (0·5mM). RH-123
ﬂuorescence was measured at 495 nm (excitation) and 525nm
(emission) under continuous stirring.
Mitochondrial respiration was determined by measuring
mitochondrial VO2 in two 2-ml air-tight thermo-stated chambers
of high resolution Oxygraph (Oxygraph2k; Oroboros)(25). The
chambers were equilibrated with the MIRO5 respiration buffer
at 37°C and fresh mitochondria were then added (0·4mg pro-
tein) followed by substrates malate–glutamate–succinate
(2·5:5:5mM, state 4) and ADP 0·5mM (state 3). Respiratory
coefﬁcient ratio was calculated as the state 3:state 4 ratio.
Mitochondrial reactive oxygen species (ROS) production was
measured on fresh mitochondria as previously described
with minor modiﬁcations(28). In brief, reaction mixtures (2ml),
containing MIRO5 buffer, dihydrodichloroﬂuorescein (10 µM) and
peroxidase (2 IU/ml), were incubated with 60µg of mitochondrial
proteins with or without substrates (malate–glutamate–succinate,
2·5:5:5mM, respectively) and with or without ADP (0·5mM).
Fluorescence was measured 30min after reaction initiation at 490/
525nm excitation and emission, respectively.
Measurement of mitochondrial enzyme activities
Citrate synthase (CS) was used as the mitochondrial marker
and measured in the muscle supernatants according to Srere(29).
The activities of the four mitochondrial respiratory complexes
(complex I, complex II, complex II + III and complex IV)
were determined spectrophotometrically(23). ATPase activity
(complex V) was determined as described by Teodoro et al.(30)
with minor modiﬁcations(23). Moreover, enzymatic activity of
mitochondrial medium-chain acyl-CoA dehydrogenase (MCAD)
and β-hydroxyacyl-CoA dehydrogenase (β-HAD) was determined
spectrophotometrically(31,32). Mitochondrial aconitase, reported as a
good marker of oxidative stress in oxidative pathologies, was
determined on muscle supernatants(33).
Mitochondrial oxidative phosphorylation subunits
The OXPHOS Western blotting kit (MitoSciences) containing a
cocktail of monoclonal antibodies was used to semi-quantify
the relative levels of the subunits of the mitochondrial OXPHOS
complexes: NDUFB8 20 kDa of complex I, Fe–S 30 kDa of
complex II, core 2–47 kDa of complex III and α 53 kDa subunit
of ATP synthase(34). For detection of OXPHOS subunits, all
Western blot steps were followed.
Muscle lipid analysis
Muscle samples were homogenised in NaCl (9 g/l) and Triton
X-100 (0·1%), and levels of FFA, TAG and total cholesterol were
quantiﬁed on the muscle homogenate by enzymatic methods
(Wako NEFA-C kit; Oxoid; Cholesterol RTU kit and triglycerides
PAP kit; Biomérieux).
Muscle ceramide content and enzymes of ceramide
metabolism
The muscle content of ceramide species (C14 : 0, C16 : 0, C18 : 0,
C18 : 1, C20 : 0, C24 : 0, C24 : 1) was determined by means of
ultra-HPLC according to Blachnio-Zabielska et al.(35). The activities
of the key enzymes implicated in ceramide metabolism – serine
palmitoyltransferase (SPT) and neutral sphingomyelinases
(nSMase) and acidic sphingomyelinases), enzymes responsible for
ceramide generation, and neutral ceramidase (nCDase) and acidic
ceramidase, enzymes responsible for ceramides degradation –were
measured using radiolabelled substrates with liquid scintillation
counter as previously described(36).
Muscle diacylglycerol content in muscle lipid extracts by
TLC-densitometry
Muscle lipids were extracted using a mixture of chloroform–
methanol (2:1, v/v) in the presence of butylated hydroxytoluene
(50mg/l). The application of lipid extracts of muscle homogenate
on silica gel 60 HPTLC plates (250µm, 20×10 cm; Merck),
pre-treated with 1·5% p/v boric acid in ethanol (100%), was
automatically performed on a 4-mm band width using a CAMAG
ATS4 apparatus. Two developments were performed, ﬁrst with
pentane–chloroform–methanol (52:45:3, by volume) on 60-mm
migration distance and second with pentane–diethyl ether (97:3
by volume) on 67-mm migration distance, which allowed the
separation of neutral lipids. The scanning of the plates was carried
out using a CAMAG TLC scanner 3 operating in the reﬂectance
mode. The plates were scanned at 550nm after dipping in a
solution of copper sulphate 640mM in H3PO4 1·18M and heating
for 20min at 180°C. The 1-monoacylglycerol (MAG), 1,2-DAG
and 1,3-DAG contents were ﬁnally identiﬁed by comparing their
retention factor (Rf) with authentic standards and were quantiﬁed
using calibration curves of the same standards.
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Phospholipid classes in muscle lipid extracts by
TLC-densitometry
Muscle lipids were extracted using a mixture of chloroform–
methanol (2:1, v/v) in the presence of butylated hydroxytoluene
(50mg/l). P was quantiﬁed to determine total muscle
phospholipids(37). The application of muscle chloroform–
methanol extracts on silica gel 60 HPTLC plates (250 µm,
20× 10 cm), pre-treated with 2·3% p/v boric acid in ethanol
(100%), was automatically performed on a 4-mm band width
using a CAMAG ATS4 apparatus. The development was
performed with methanol–acetic acid–pentane–chloroform
(15:10:30:45, by volume), which allowed the separation of
phospholipids and neutral lipids on a 60-mm total migration
distance. The scanning of the plates was carried out using a
CAMAG TLC scanner 3, operating in the reﬂectance mode. The
plates were scanned at 715nm after dipping in a solution of
Blue Spray (1:2:3, v/v/v, Blue Spray–H2SO4 4·2M–acetone) and
heating for 3min at 55°C. The different classes of phospholipids
(phosphatidylcholine (PC); phosphatidylethanolamine (PE);
phosphatidylinositol (PI); phosphatidylserine (PS); sphingomyelin
(SM); lysophosphatidylcholine (LPC); phosphatidylglycerol
(PG); phosphatidic acid (PA) and cardiolipin (CL)) were ﬁnally
identiﬁed by comparing their Rf with authentic standards and
were quantiﬁed using calibration curves of the same standards(38).
Fatty acid composition of muscle and muscle phospholipids
Determination of fatty acid composition of the total muscle lipids
was carried out using the muscle chloroform–methanol extracts.
To determine the fatty acid composition of the muscle
phospholipids, the phospholipid fraction was separated from
other muscle neutral lipids on TLC plates with hexane–diethyl
ether–glacial acetic acid mixture (70:30:1, v/v/v). Plates were
dried and sprayed with dichloroﬂuorescein. Bands corresponding
to phospholipids were identiﬁed under UV and collected
by scraping the silica into a glass tube for further analysis. The
dried muscle chloroform–methanol extract and the scraped
phospholipid bands were trans-esteriﬁed with an alkali mixture
of KOH–methanol for 10min at room temperature. The total
fatty acid methyl ester pattern was analysed by GC (Agilent
Technologies) equipped with a DB-23 column and a ﬂame
ionisation detector. Chromatograms were collected, and peaks
were integrated and identiﬁed by comparison with commercially
available references.
Table 1. Effects of diets on diet consumption, rat body evolution and tissue weights*
(Mean values and standard deviations; n 6–8 observations)
Control HF HF+MitoQ
Mean SD Mean SD Mean SD
Initial weight 197 6 197 5 197 6
Final weight 581a 32 632b 36 597a,b 45
Diet intake (g/rat per d) 26·9a 1·0 20·6b 0·9 18·4c 1·0
Energy intake (kJ/rat per d) 406 17 464 21 418 21
Energy intake (kcal/rat per d) 97a 4 111b 5 100a 5
Liver (g) 14·0a 1·0 17·1b 2·0 15·4a,b 2·3
Adipose tissue (g) 54·1a 9·6 78·4b 15·7 65·7a,b 10·3
Gastrocnemius (g) 6·52 0·34 6·33 0·39 6·29 0·46
HF, high fat.
a,b,cMean values with unlike superscript letters in the same row were significantly different. The limit of statistical significance was set at P< 0·05.
* Rats were fed their corresponding diets for 8 weeks; 16-h fasted rats were killed and liver, muscles and adipose tissues were sampled, rinsed with physiological solution, weighed
and aliquoted and frozen for analysis. To detect statistical significance among groups, one-way ANOVA test, followed by Fischer’s post hoc analysis, was applied for normally
distributed data checked by the Kolmogorov–Smirnov test.
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Fig. 1. Body weight gain in rats fed either (1) control (cont, ) , (2) high fat
(HF, ) or (3) HF+MitoQ ( ) diets for 8 weeks. Values are means (n 7–8
observations), and standard deviations. Statistical significance among groups
was detected as described in the statistical analysis section. The limit of
statistical significance was set at P<0·05. In all, twenty-four 6-week-old male
Sprague–Dawley rats, weighing 175–200g, were randomised into three groups
of eight animals each and fed their corresponding diets for 8 weeks. Rats were
given free access to tap water and food, and body weight and food
consumption were determined weekly. MitoQ, mitochondrial-targeted
lipophilic ubiquinone; HF+MitoQ, HF with MitoQ.
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Statistical analysis
The sample size was calculated from the expected difference in the
AUC of the OGTT between the control group and the HFD group.
We expected an AUC about 1·20 times greater in the HF group
than in the control group. A standard deviation of 15% of the
higher value could be allowed. For a type 1 risk α of 0·05 and
power (1-β) of 80%, the sample size required was eight per group.
Data are expressed as mean values and standard deviations.
Normal distribution of data was checked by the Kolmogorov–
Smirnov test. To detect statistical signiﬁcance among groups,
one-way ANOVA test, followed by Fischer’s post hoc analysis,
was applied for normally distributed data. Data not following
normal distribution were analysed by non-parametric tests
using the Kruskal–Wallis method followed by Dunn’s post hoc
analysis and marked with †. The limit of statistical signiﬁcance
was set at P< 0·05. Statistical analyses were performed using the
StatView program (SAS Institute).
Results
Mitochondrial-targeted lipophilic ubiquinone intake prevented
weight gain, glucose intolerance and muscle lipid accumulation
Although the dietary intake (g/d) was decreased, the energy intake
was signiﬁcantly increased in the HF group but not in the MitoQ
group (Table 1). Therefore, the ﬁnal rat body weight was
signiﬁcantly increased in the HF group compared with the control
group, whereas MitoQ intake prevented weight gain (Fig. 1).
Moreover, the weight of both liver and adipose tissue was
increased in the HF groups, but this increase was largely attenuated
by MitoQ intake. However, the weight of both gastrocnemius and
soleus muscles remained unchanged among the studied groups
(Table 1).
Two major inﬂammation markers, TNF-α and IL-6, were
determined in this study. Plasma TNF-α was increased signiﬁcantly
in the HF group and increased non-signiﬁcantly in the HF-MitoQ
group compared with the control group. However, plasma IL-6
remained unchanged in all the three experimental groups. In
addition, the gene and protein expressions of both TNF-α and IL-6
remained unchanged at the muscle level (Table 2). Although the
fasted plasma glucose level remained unchanged among the
studied groups, the AUC of the OGTT was increased in the HF
group, whereas MitoQ intake attenuated it compared with the
control group (Fig. 2). In addition, both plasma insulin level and
the HOMA-IR index were decreased by MitoQ intake v. both
control and HF groups, whereas plasma leptin was increased in
both HF and HF-MitoQ groups v. the control group (Table 2).
Surprisingly, some serum lipid parameters (TAG, NEFA and total
cholesterol) were decreased signiﬁcantly in the HF rat group and
MitoQ intake further lowered these parameters. The muscle TAG
level was statistically signiﬁcantly increased (+23%) in the HF
group v. the control group, whereas MitoQ intake completely
prevented this muscle lipid accumulation (Table 2).
Mitochondrial-targeted lipophilic ubiquinone intake
restored mitochondrial respiration
The mitochondrial membrane potential and the mitochondrial ROS
production measured ex vivo were not affected by the HFD or
MitoQ intake (Table 3). However, mitochondrial respiration
decreased signiﬁcantly with the HF diet v. control diet in the three
Table 2. Effects of diets on blood and muscle lipid, inflammation and insulin-resistance parameters*
(Mean values and standard deviations; n 6–8 observations)
Control HF HF+MitoQ
Mean SD Mean SD Mean SD
Blood parameters
Plasma glucose (mM) 8·15 1·28 7·70 0·86 8·40 0·95
Plasma insulin (µg/l)† 6·18a 1·94 6·44a 1·56 3·85b 1·89
HOMA-IR index 61·0a 19·0 61·4a 14·6 35·5b 18·6
Plasma leptin (µg/l) 4·25a 1·33 8·86b 3·16 6·48a,b 3·14
Plasma TNF-α (ng/l) 7·4a 4·4 15·4b 7·9 12·7a,b 5·6
Plasma IL-6 (ng/l) 116 14 123 20 116 22
Serum TAG (mM) 1·44 0·41 1·04 0·31 0·94 0·25
Serum FFA (µM) 596a 106 443b 84 411b 61
Serum total cholesterol (mM) 2·01a 0·29 1·55b 0·12 1·76a,b 0·21
Serum HDL-cholesterol (mM) 1·34 0·22 1·12 0·18 1·17 0·09
Muscle parameters
TAG (µmol/g ww)† 6·46a 1·42 7·93b 1·25 5·56a 1·00
FFA (µmol/g ww) 2·28 0·37 2·32 0·23 2·17 0·29
Cholesterol (µmol/g ww) 1·44 0·17 1·36 0·22 1·37 0·22
TNF-α gene expression 1·00 1·12 1·24 1·29 1·66 1·36
TNF-α protein expression 1·00 0·18 1·01 0·11 1·04 0·26
IL-6 gene expression 1·00 0·50 1·82 1·37 1·97 1·54
IL-6 protein expression 1·00 0·38 1·08 0·32 0·95 0·28
HF, high fat; HOMA-IR, homoeostasis model assessment-insulin resistance; ww, wet weight; FFA, free fatty acids.
a,b Mean values with unlike letters in the same row were significantly different. The limit of statistical significance was set at P< 0·05.
* Rats were fed their corresponding diets for 8 weeks; 16-h fasted rats were killed and blood and muscles were sampled. The muscle was rinsed with physiological solution, weighed
and aliquoted and frozen for analysis. To detect statistical significance among groups, one-way ANOVA test, followed by Fischer’s post hoc analysis, was applied for normally
distributed data checked by the Kolmogorov–Smirnov test.
† Data not following normal distribution were analysed by non-parametric tests using the Kruskal–Wallis method followed by Dunn’s post hoc analysis.
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studied conditions: mitochondria challenged with glutamate–
malate or with glutamate–malate–succinate or with G/M/S
plus ADP. MitoQ intake signiﬁcantly increased mitochondrial
respiration back to control values (Fig. 3). However, mitochondrial
CS activity, enzymatic activity and the protein expression
of mitochondrial chain complexes also remained unchanged
in the studied groups (Table 3). Finally, mitochondrial β-oxidation
was investigated by assessing the enzymatic activity of two
major enzymes (β-HAD and MCAD) in this pathway. The activity
of these two enzymes remained unchanged in the studied
groups (Table 3).
Mitochondrial-targeted lipophilic ubiquinone intake was
without effect on diacylglycerol content, but decreased
muscle enzymatic activities of ceramide metabolism
The muscle MAG as well as DAG contents were not signiﬁcantly
affected by either the HF diet or MitoQ intakes (Table 4).
However, the HF diet intake trended to increase the muscle
content of both 1,2-DAG (+15%) and 1,3-DAG (+22%),
whereas MitoQ tended to decrease both DAG contents back to
the control values (−10 and −31%, respectively).
The total content of muscle ceramides did not change by the
HF diet or MitoQ intake. However, some species of ceramides
(C14, C16, C18 : 1, C22 and C24 : 1) were signiﬁcantly decreased
by HF diet intake while MitoQ administration was without effect.
The major ceramide species, the C18, as well as the C20 and C24,
remained unchanged in the three studied groups (Table 4).
The activities of the key enzymes implicated in ceramide and
SM metabolism showed that SPT activity was decreased non-
signiﬁcantly (−14%) in both HF and HF-MitoQ diets v. control
diet, whereas the activity of both nCDase and nSMase were
increased only in the HF diet v. control diet. Interestingly, the
MitoQ intake decreased signiﬁcantly the activity of these two
enzymes back to control values (Table 4).
Mitochondrial-targeted lipophilic ubiquinone intake
decreased the percentage of sphingomyelin in the muscle
The major ﬁnding from the muscle phospholipid analysis was
the signiﬁcant increase in the SM percentage and in the SM:PC
ratio with the HF diet compared with the control diet. Inter-
estingly, MitoQ intake was proved to be efﬁcient in normalising
SM per cent and SM:PC ratio to control levels (Table 5). The
percentage of the other phospholipid classes (LPC, PC, PI, PS,
PE, PG, PA and CL) was not altered by either the HF diet or
MitoQ intake.
Mitochondrial-targeted lipophilic ubiquinone intake
increased muscle PUFA n-3%
We have analysed the effects of the HF diet and MitoQ intake
on the fatty acid composition of total muscle lipids (Table 6).
The percentage of total and individual SFA (C16 : 0 and C18 : 0)
remained unchanged. Apart from this, the HF diet intake was
associated with a decrease in 16 : 1 n-7 and 18 : 1 n-7 and with
an increase in 18 : 1 n-9% (+100%), and as a consequence a
strong tendency for an increase in the level of total MUFA
(+45%). The MitoQ intake only slightly decreased the 18 : 1
n-9% (−20%) and the total MUFA percentage (−18%) in the
total muscle lipid compared with the HF diet. The HF diet intake
also increased non-signiﬁcantly the C22 : 5 n-3% and decreased
signiﬁcantly the C22 : 6 n-3%, with an overall decrease in the
percentage of total PUFA n-3 in the total muscle lipid (Table 6).
Interestingly, MitoQ intake increased signiﬁcantly the total
PUFA n-3% (+28%), particularly that of C22 : 5 n-3 (+19%) and
C22 : 6 n-3 (+25%), compared with the HF diet (Table 6).
Mitochondrial-targeted lipophilic ubiquinone intake
decreased the percentage of MUFA in the muscle
phospholipids
The HF diet and MitoQ intake were without effect on the
percentage of total or individual SFA in muscle phospholipids,
although the per cent of C18 : 0 was non-signiﬁcantly
increased (+15%) with HF diet and MitoQ intake (Table 7).
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Fig. 2. Glucose tolerance test in 16-h fasted rats fed either control (cont, ) ,
high-fat (HF, ) or HF+MitoQ ( ) diets for 8 weeks. Values are means
(n 7–8 observations), and standard deviations represented by vertical bars.
Statistical significance among groups was detected as described in the statistical
analysis section. The limit of statistical significance was set at P<0·05. a,bGroup
mean values with unlike letters were significantly different. In all, twenty-four 6-week-
old male Sprague–Dawley rats, weighing 175–200g, were randomised into three
groups of eight animals each and fed their corresponding diets for 8 weeks. Rats
were given free access to tap water and food, and body weight and food
consumption were determined weekly. MitoQ, mitochondrial-targeted lipophilic
ubiquinone; HF+MitoQ, HF with MitoQ.
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On the contrary, the MUFA per cent was highly impacted.
The HF diet and MitoQ intake were associated with a signiﬁcant
decrease in the percentages of 16 : 1 n-7 and 18 : 1 n-7, with a
strong tendency for a decrease in total MUFA per cent with
MitoQ intake (−20%) (Table 7). The HF diet and MitoQ intake
did not affect the PUFA n-6%, although the per cent of C20 : 4,
n-6 was increased non-signiﬁcantly and signiﬁcantly with HF
diet and MitoQ, respectively. The HF diet intake decreased
signiﬁcantly the PUFA n-3%, whereas MitoQ intake
slightly prevented this decrease. Indeed, HF diet and
MitoQ intake increased the C22 : 5 n-3% and decreased the
C22 : 6 n-3% (Table 7).
Discussion
We have investigated the impact of MitoQ, on the development
of the metabolic syndrome features in obesogenic diet-fed rats.
The results of this study show that the HF diet led to a moderate
gain in weight and glucose intolerance associated with slight
low-grade inﬂammation, intramuscular lipid accumulation,
membrane phospholipid modiﬁcation and alteration in
muscular mitochondrial respiration. In particular, the HF
diet signiﬁcantly increased the muscle levels of both TAG and
SM and signiﬁcantly decreased the muscle PUFA n-3 level.
In addition, these HF diet-induced lipid modiﬁcations were
accompanied with signiﬁcant decrease in muscle mitochondrial
respiration. Interestingly, MitoQ intake prevented body weight
gain, improved glucose tolerance, corrected the observed
lipid alterations and restored mitochondrial respiration.
These results suggest that muscle lipid modulation and
mitochondrial respiration restoration by MitoQ intake may
mediate the prophylactic action of MitoQ in some metabolic
syndrome features in HFD-fed rats. Although our results show
that MitoQ intake was accompanied by slight but signiﬁcant
decrease in food and energy intakes (about −10%) compared
with the HF group, the food consumption was rather stable
during the whole experimental period, and thus the cause
for this food intake decrease did not seem to be due to
food aversion. The mechanism involving decreased energy
intake with MitoQ may be mediated at the hypothalamic level
as reported by Fink et al.(39) for the effects of quinols in
mice fed HFD.
Low-grade inﬂammation is a characteristic of the obese state,
and adipose tissue is known to release many inﬂammatory
mediators. In this study, the HF intake was accompanied with
signiﬁcant increase in plasma TNF-α, but not in IL-6 levels,
whereas MitoQ only slightly attenuated this increase. However,
muscle gene and protein expressions of these two cytokines
were not altered by either the HF diet or MitoQ intake. It is
highly likely that the source of this increased plasma TNF-α
level is the adipose tissue, which is known to be the major
sources of body cytokines.
One intriguing ﬁnding is that MitoQ intake decreased the
plasma insulin level compared with both control and HF diet
groups. This may suggest that MitoQ somehow increased
insulin sensitivity. The decreased insulin levels could also
suggest a decreased glucose-stimulated insulin release at the
Table 3. Effects of diets on mitochondrial activity*
(Mean values and standard deviations; n 6–8 observations)
Control HF HF+MitoQ
Mean SD Mean SD Mean SD
Mitochondrial ROS production (pmol H2O2/min per mg protein)
Mitochondria +G/M/S 636 145 580 147 650 145
Mitochondria +G/M/S +ADP 281 87 289 100 329 118
Mitochondrial membrane potential (arbitrary units/mg protein)
Mitochondria alone 64·0 5·9 62·9 5·6 65·0 4·3
Mitochondria +G/M/S 76·9 2·9 77·2 2·2 78·3 2·2
Mitochondria +G/M/S +ADP 53·1 5·2 53·1 3·6 54·3 4·5
Enzymatic activity of muscle respiratory chain complexes (mU/mg protein)
Citrate synthase 630 76 633 70 646 66
Complex I 115 12 119 31 114 18
Complex II 195 25 205 62 198 28
Complexes II + III 31·5 5·0 34·3 6·5 37·6 6·8
Complex IV 179 36 195 52 201 38
Protein expression of muscle respiratory chain complex (WB)
Complex I 1·00 0·35 0·91 0·34 0·97 0·30
Complex II 1·00 0·46 1·04 0·37 1·06 0·57
Complex III 1·00 0·37 0·98 0·17 1·01 0·32
Complex V 1·00 0·31 1·03 0·22 1·03 0·33
Activity of other mitochondrial enzymes (mU/mg protein)
MCAD 18·3 2·9 17·8 2·7 19·3 1·6
β-HAD 281 35 303 28 314 37
HF, high fat; ROS, reactive oxygen species; G, glutamate; M, malate; S, succinate; MCAD, medium-chain acyl-CoA dehydrogenase; β-HAD, β-hydroxyacyl-CoA dehydrogenase.
The limit of statistical significance was set at P< 0·05. There were no significant differences among the three experimental groups for all the stated parameters.
* Rats were fed their corresponding diets for 8 weeks; 16-h fasted rats were killed and muscles were sampled, rinsed with physiological solution, weighed and aliquoted and frozen
for analysis. To detect statistical significance among groups, one-way ANOVA test, followed by Fischer’s post hoc analysis, was applied for normally distributed data checked by
the Kolmogorov–Smirnov test.
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pancreas level. However, as we did not sample the pancreas of
these animals in the present study, these hypotheses will be
addressed in future studies.
Because of the key role of mitochondria in lipid metabolism,
obesity and IR, and because of the characteristics of MitoQ as a
mitochondrial-targeted quinone, we have determined many
surrogate parameters to evaluate muscle mitochondrial function
and activity in this study. Both HF diet and MitoQ intake showed
no notable effect on mitochondrial biogenesis as determined by
CS activity and mitochondrial DNA. Ex vivo mitochondrial
membrane potential, ROS production and activity and protein
content of mitochondrial respiratory complexes, as well as
mitochondrial β-oxidation activity, as measured by β-HAD and
MCAD activities also remained unchanged in the three studied
groups. In addition, there were no signiﬁcant changes in either
protein expressions or enzymatic activities of the mitochondrial
respiratory chain complexes. However, the muscle mitochondrial
respiration/VO2 was decreased with the HF diet and was rees-
tablished to the control value by MitoQ intake. The MitoQ intake
restored this mitochondrial respiration probably by both mod-
ulating the fatty acid composition of mitochondrial
membranes and increasing the mitochondrial quinone pool.
Indeed, the later is involved as an electron and proton carrier in
mitochondrial respiration, and can act in its reduced form as an
antioxidant improving mitochondrial respiration as reported by
Jiménez-Santos et al.(40). This enhanced mitochondrial respiration
may lead to higher fat oxidation, and thus to changes in
intramuscular lipid content and composition, which may mediate
the prophylactic action of MitoQ on some aspects of the metabolic
syndrome. However, one limitation of ex vivo measurement of
mitochondrial respiration is that the muscle mitochondria were not
in their natural environment, and thus we should be cautious in
the interpretation of these particular results.
Muscle lipid accumulation and/or lipid metabolism alteration is
thought to play an important role in the development of IR in HF
feeding models(41,42). Although many reports have reported
increased muscle lipid accumulation in mice/rats fed HFD, the
intracellular toxic metabolites (fatty acyl CoA, DAG, ceramides and
SM) are considered to be the true culprits of IR that may impair
insulin signalling to glucose metabolism(42–44). In line with this, the
results of this study show that the muscle lipid proﬁle is altered in
our obesogenic diet-fed rats. The HF intake has altered different
major actors of lipid metabolism and signalling – that is, (1) an
increase in activities of key enzymes implicated in muscle
ceramide metabolism; (2) an increase in muscle SM% and
(3) a decrease in the PUFA n-3% with the HF diet. Interestingly,
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Fig. 3. Muscle mitochondrial respiration in rats fed either control (cont), high-fat (HF) or HF+MitoQ diets for 8 weeks. Values are means (n 7–8 observations), and
standard deviations represented by vertical bars. Rats were fed their corresponding diets for 8 weeks; 16-h fasted rats were killed and muscles were sampled, rinsed
with physiological solution and fresh mitochondria were isolated. (A) Mitochondria were challenged by malate + glutamate. (B) Mitochondria were challenged by malate
+glutamate+succinate. (C) Mitochondria were challenged by malate+glutamate+succinate plus ADP. (D) Respiratory coefficient ratio (state 3/state 4). To detect
statistical significance among groups, a one-way ANOVA test, followed by Fischer’s post hoc analysis, was applied for normally distributed data checked by the
Kolmogorov–Smirnov test. The limit of statistical significance was set at P< 0·05. a,bMean values with unlike letters for the same parameter were significantly different.
† Data not following normal distribution were analysed by non-parametric tests using the Kruskal–Wallis method followed by Dunn’s post hoc analysis.
MitoQ, mitochondrial-targeted lipophilic ubiquinone; HF+MitoQ, HF with MitoQ.
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the MitoQ intake has led to the normalisation of these
parameters nearly to the control values.
The HF diet intake was accompanied by a slight decrease in
total ceramide content (−9·5%) and led to a signiﬁcant decrease
in selective ceramide species. This may arise from diminished
de novo ceramide synthesis (slight low SPT activity in both HF
diet groups), and from its increased degradation by activation of
nCDase. However, the high sphingomyelinase (SMase) activity
can also balance the high nCDase activity; thus, ceramide does
not highly accumulate in skeletal muscle due to its faster
turnover rate. Although MitoQ intake decreased signiﬁcantly the
activity of these two enzymes back to control values,
this was without effect on muscle total ceramide or ceramide
species contents. If some reports indicated increased
muscle ceramide content after HF diet intake(45,46), other
reports failed to show such an increase(47). This may be due to
the type of dietary lipids, the experiment duration and the
muscle type(45).
Table 4. Muscle diacylglycerol (DAG) and ceramide contents and enzymes of ceramide metabolism*
(Mean values and standard deviations; n 6–8 observations)
Control HF HF+MitoQ
Mean SD Mean SD Mean SD
MAG and DAG content (µg/g tissue)
MAG† 58·9 7·6 63·6 11·2 55·8 4·9
1,2-DAG 86·6 29·3 100·0 35·7 89·8 44·5
1,3-DAG† 11·2 4·3 13·7 6·5 9·4 2·8
Total DAG 97·8 32·7 114·1 40·7 99·2 46·7
Ceramide species content (pmol/g tissue)†
Ceramide C14 4·26a 2·81 1·21b 0·40 1·12b 0·32
Ceramide C16 2146a 635 979b 193 1006b 201
Ceramide C18 27 955 4113 28099 5726 28 942 1606
Ceramide C18 : 1 237a 33 155b 55 156b 19
Ceramide C20 101 33 83 32 89 18
Ceramide C22 1157a 301 801b 309 867b 145
Ceramide C24 4333 1557 3455 1345 3535 767
Ceramide C24 : 1 4304a 704 2870b 1003 3074b 408
Total ceramides 40 238 5684 36445 7813 37 700 2169
Enzymatic activity of ceramide metabolism (pmol/min per mg protein)
Serine palmitoyltransferase 8·67 1·67 7·50 1·83 7·50 1·33
Neutral sphingomyelinase† 248a 62 323b 105 220a 43
Acidic sphingomyelinase 265 72 273 60 252 75
Neutral ceramidase 21·0a 3·3 27·8b 9·2 19·5a 6·8
Acidic ceramidase 3·17 6·00 3·83 5·50 6·50 2·50
HF, high fat; MAG, 1-monoacylglycerol.
a,b Mean values with unlike letters in the same row were significantly different. The limit of statistical significance was set at P< 0·05.
* Rats were fed their corresponding diets for 8 weeks; 16-h fasted rats were killed and muscles were sampled, rinsed with physiological solution, weighed and aliquoted and frozen
for analysis. To detect statistical significance among groups, one-way ANOVA test, followed by Fischer’s post hoc analysis, was applied for normally distributed data checked by
the Kolmogorov–Smirnov test.
† Data not following normal distribution were analysed by non-parametric tests using the Kruskal–Wallis method followed by Dunn’s post hoc analysis.
Table 5. Effects of diets on muscle phospholipid content and their class distribution*
(Mean values and standard deviations; n 6–8 observations)
Control HF HF+MitoQ
Parameters Mean SD Mean SD Mean SD
Total phospholipids (µmol P/g ww) 13·7 1·2 14·5 1·3 14·4 1·1
PC (%) 54·9 1·8 53·4 2·0 55·4 1·2
PE (%) 25·1 1·3 25·8 1·7 24·8 1·5
Cardiolipin (%) 7·74 0·66 8·04 0·78 8·29 0·54
Phosphatidylinositol (%) 5·28 0·56 5·15 0·57 5·02 0·67
Phosphatidylserine (%) 2·95 0·29 2·78 0·50 2·58 0·50
SM (%) 3·96a 0·67 4·86b 0·99 3·90a 0·49
(SM/PC) × 100 7·23a 1·38 9·15b 2·13 7·05a 0·90
(PE/PC) × 100 45·8 3·8 48·4 4·7 44·8 3·6
HF, high fat; ww, wet weight; PC, phosphatidylcholine; PE, phosphatidylethanolamine; SM, sphingomyelin.
a,b Mean values with unlike letters in the same row were significantly different. The limit of statistical significance was set at P< 0·05.
* Rats were fed their corresponding diets for 8 weeks; 16-h fasted rats were killed and muscles were sampled, rinsed with physiological solution, weighed and aliquoted and frozen
for analysis. To detect statistical significance among groups, one-way ANOVA test, followed by Fischer’s post hoc analysis, was applied for normally distributed data checked by
the Kolmogorov–Smirnov test.
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SM signalling pathway in muscle is an important factor
determining the development of IR(48) and an important direct
precursor for ceramide under the action of many different
SMase(49). In this study, we have found that the HF intake
increased muscle SM level, whereas MitoQ intake returned it to
the control level. Indeed, the higher enzymatic activity of
nSMase by MitoQ may be responsible for this SM decrease. SM
synthase was not measurable to better determine the origin of
SM increase in the HF group.
It is generally accepted that the type of dietary fat plays a far
more signiﬁcant role in health and disease than its absolute
amount(50). The Western diet, characterised by excessive amounts
of SFA, n-6 PUFA and trans fatty acids with decreased intake of n-3
PUFA, has been implicated in chronic diseases such as obesity,
diabetes and CVD. In parallel, epidemiological, human and animal
studies suggest that increased dietary n-3 PUFA may decrease the
risk factors for the metabolic syndrome including central adiposity,
hyperglycaemia, IR and dyslipidaemia(51). Indeed, although the
Table 6. Effects of diets on fatty acid composition (%) of total lipids from muscle homogenate*
(Mean values and standard deviations; n 6–8 observations)
Control HF HF+MitoQ
Fatty acids Mean SD Mean SD Mean SD
16 : 0 22·6 1·8 22·2 1·1 21·6 0·9
18 : 0 9·18 1·66 10·3 1·1 10·1 1·5
Total SFA 31·8 1·0 32·5 1·8 31·7 1·6
16 : 1 n-7† 2·87a 0·85 1·65b 0·55 1·57b 0·44
18 : 1 n-7† 4·31a 0·34 3·28b 0·19 3·06b 0·26
18 : 1 n-9† 9·78a 4·2 20·5b 6·9 16·1b 6·7
Total MUFA 17·8a 5·4 25·9b 7·4 21·3a,b 7·5
18 : 2 n-6 17·8 2·3 17·6 2·3 18·2 0·9
20 : 3 n-6 0·53 0·09 0·53 0·18 0·54 0·15
20 : 4 n-6† 14·6 2·5 12·4 3·5 15·7 2·1
Total n-6 PUFA† 34·9 3·5 30·8 5·7 33·2 5·5
18 : 3 n-3 0·50 0·18 0·47 0·14 0·48 0·21
22 : 5 n-3 1·94a 0·46 2·32a,b 0·62 2·75b 0·53
22 : 6 n-3 11·7a 2·4 7·83b 1·77 9·75a,b 2·38
Total n-3 PUFA 15·5a 3·7 10·8b 2·3 13·8a 2·6
Total PUFA† 50·4a 5·8 41·6b 7·8 47·0a,b 8·0
HF, high fat.
a,b Mean values with unlike letters in the same row were significantly different. The limit of statistical significance was set at P< 0·05.
* Rats were fed their corresponding diets for 8 weeks; 16-h fasted rats were killed and muscles were sampled, rinsed with physiological solution, weighed and aliquoted and frozen
for analysis. To detect statistical significance among groups, one-way ANOVA test, followed by Fischer’s post hoc analysis, was applied for normally distributed data checked by
the Kolmogorov–Smirnov test.
† Data not following normal distribution were analysed by non-parametric tests using the Kruskal–Wallis method followed by Dunn’s post hoc analysis.
Table 7. Effects of diets on fatty acid composition (%) of muscle phospholipids*
(Mean values and standard deviations; n 6–8 observations)
Control HF HF+MitoQ
Fatty acids Mean SD Mean SD Mean SD
16 : 0 22·9 2·5 21·2 0·9 21·7 1·6
18 : 0 13·2 1·9 15·1 1·9 15·3 1·8
Total SFA 36·0 3·2 36·3 1·6 36·8 1·0
16 : 1 n-7† 1·34a 0·30 0·48b 0·09 0·42b 0·07
18 : 1 n-7† 4·65a 0·40 3·11b 0·19 3·10b 0·16
18 : 1 n-9† 5·04a 0·88 8·01b 2·72 5·94a 0·55
Total MUFA† 11·2a 1·3 11·8a 2·7 9·58b 0·62
18 : 2 n-6† 16·9 2·4 16·4 2·3 16·5 1·5
18 : 3 n-6 0·05 0·02 0·03 0·02 0·03 0·02
20 : 3 n-6 0·64 0·11 0·73 0·10 0·72 0·10
20 : 4 n-6 17·2a 1·3 18·0a 0·6 19·2b 1·1
Total n-6 PUFA 35·2 1·8 35·5 2·3 35·9 2·7
18 : 3 n-3 0·22 0·011 0·14 0·14 0·23 0·21
20 : 5 n-3 0·14 0·03 0·13 0·02 0·12 0·01
22 : 5 n-3 2·51a 0·35 3·63b 0·44 3·63b 1·05
22 : 6 n-3 14·0a 2·0 12·4b 1·0 12·5b 0·7
Total n-3 PUFA 18·2a 2·0 16·4b 1·3 16·8a,b 0·6
Total PUFA 53·8 2·7 51·8 1·9 53·6 1·2
HF, high fat.
a,b Mean values with unlike letters in the same row were significantly different. The limit of statistical significance was set at P< 0·05.
* Rats were fed their corresponding diets for 8 weeks; 16-h fasted rats were killed and muscles were sampled, rinsed with physiological solution, weighed and aliquoted and frozen
for analysis. To detect statistical significance among groups, one-way ANOVA test, followed by Fischer’s post hoc analysis, was applied for normally distributed data checked by
the Kolmogorov–Smirnov test.
† Data not following normal distribution were analysed by non-parametric tests using the Kruskal–Wallis method followed by Dunn’s post hoc analysis.
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exact mechanisms of action of n-3 PUFA remain unclear, many
possible effects of n-3 PUFA on muscle metabolism related to
glucose tolerance and insulin sensitivity have been proposed(52).
These include potent anti-inﬂammatory actions mediated directly
by their metabolites such as resolvins and protectins(53) and
indirectly via the activation of their functional receptor GPR120 that
blocks the major NF-κB inﬂammation pathway(54). The inhibition of
inﬂammatory cytokine production by n-3 PUFA decreases in turn
sphingolipid synthesis, particularly ceramide and SM(55). Moreover,
n-3 PUFA may induce a modiﬁcation in fatty acid composition of
membrane phospholipids, associated with the production of
structurally different DAG that may participate in some of the
protective effects of n-3 PUFA against various chronic diseases,
including IR and diabetes type II(56). In line with this, Lanza et al.(57)
have shown that n-3 PUFA protect glucose tolerance, in part by
preventing the accumulation of bioactive lipid mediators that
interfere with insulin action. The results of the present study show
that the HF diet decreased the muscle n-3 PUFA content, and
the intake of the mitochondrial-targeted antioxidant MitoQ
reestablished it to the control level. This effect may be in part
responsible for the favourable effects of MitoQ on body glucose
tolerance and insulin sensibility.
In conclusion, the HFD used in this study for 8 weeks was
effective at inducing the major features of the metabolic
syndrome in our rats – namely, moderate obesity, glucose
intolerance associated with muscle mitochondrial dysfunction
and marked alteration in lipid composition. Indeed, important
modiﬁcations in the muscle PL classes (increase in SM and in
the SM:PC ratio) in fatty acid composition of total muscle lipids
and those of muscle PL (increase in MUFA, particularly C18 : 1
n-9, and decrease in PUFA, particularly PUFA n-3)
were observed. In addition, these lipid modiﬁcations were
accompanied by a signiﬁcant decrease in mitochondrial
respiration. All these modiﬁcations could contribute to the
development of the obesity, glucose intolerance and IR
observed in these rats. Interestingly, MitoQ intake corrected the
lipid alterations (decreased muscle TAG, SM and C18 : 1 n-9 and
increased PUFA n-3 levels) and restored mitochondrial
respiration. Collectively, these results suggest that MitoQ
protected rats exposed to a HFD from some metabolic syn-
drome features probably through lipid metabolism
modulation and mitochondrial activity improvement. These
ﬁndings suggest that MitoQ and related mitochondrial-targeted
ubiquinones are promising candidate compounds for future
clinical studies in preventing the metabolic syndrome.
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